FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2991856492> ?p ?o ?g. }

• W2991856492 abstract "Abstract Background: Therapy of Hodgkin lymphoma (HL) can contribute to delayed impairments of health, which some of them (e.g. secondary cancer) can be fatal. Aim: The purpose of this retrospective study was to evaluate long-term outcome of HL survivors and the risk of second malignancies. Methods: The medical report data analysis of 170 patients (pts) with HL treated in one oncological center in Poland between 1979–2005 has been performed. There were 88 females and 82 males, median age 30.5 years (range 16–72). Among the patients there were 22 pts (12.5%) in CSI, 95 pts (55.8%) in CSII, 26 pts (15.4%) in CSIII and 27 pts (15.8%) in CSIV. Half of the 170 pts presented B-symptoms. Chemotherapy (ABVD, MOPP/ABV or MOPP regimen) was given to 155 (93.5%) pts, and radiotherapy alone (mantle-field or involved-field) was given to 11 pts (6.5%). Chemoradiotherapy received 105 pts (61.8%). Results: CR achieved 136 pts (80%), PR 11 pts (6.4%), and progression of HL was observed in 23 pts (13.5%). With a median follow-up of 242 months (range 0–439), there were 37 relapses (21.7%), and 25 deaths (14.7%), usually due to HL progression (20 pts), and also because of secondary cancer (4 pts = 2.4%) and coronary heart disease (1 patient). Five year DFS and OS were 80% and 90% respectively. There was no statistical difference between ABVD and MOPP/ABV regimen efficacy (p=0.94). Late impairments of health were revealed in 78 pts (45.9%), and there were: secondary malignancies, amenorrhea/infertility, skeletal lesions, depressive syndromes, pulmonary fibrosis, polyneuropathy, hypothyroidism, cardiovascular disease, and gastro-duodenal peptic ulcer. Nine pts (5,3%) developed secondary malignancies, i.e.: 2 melanomas, 2 skin basal-cell carcinomas, 1 osteosarcoma, 1 thyroid carcinoma, 1 non-small cell lung cancer, 1 colon carcinoma, 1 cervical carcinoma, and 1 prostate carcinoma. A median time from the end of the treatment to the development of secondary cancer was 114 months (range 28–434). The risk of secondary malignancies development among pts treated with either initial chemotherapy alone or combined modality therapy was similar, and did not reach statistical significance (p=0.20). Conclusions: Chemotherapy or chemoradiotherapy of HL provides freedom from the disease in more than 3/4 of our patients. In the group of fairly young patients such treatment caused a substantial amount of variety of health impairments including secondary malignancies. Despite the high rate of HL curability our study indicates the need of a careful, long term medical surveillance of HL survivors." @default.
• W2991856492 created "2019-12-13" @default.
• W2991856492 creator A5005623067 @default.
• W2991856492 creator A5008968972 @default.
• W2991856492 creator A5014007160 @default.
• W2991856492 creator A5045513298 @default.
• W2991856492 date "2008-11-16" @default.
• W2991856492 modified "2023-09-29" @default.
• W2991856492 title "Analysis of Long-Term Outcome and the Risk of Second Malignancies in Hodgkin Lymphoma Survivors" @default.
• W2991856492 doi "https://doi.org/10.1182/blood.v112.11.4953.4953" @default.
• W2991856492 hasPublicationYear "2008" @default.
• W2991856492 type Work @default.
• W2991856492 sameAs 2991856492 @default.
• W2991856492 citedByCount "0" @default.
• W2991856492 crossrefType "journal-article" @default.
• W2991856492 hasAuthorship W2991856492A5005623067 @default.
• W2991856492 hasAuthorship W2991856492A5008968972 @default.
• W2991856492 hasAuthorship W2991856492A5014007160 @default.
• W2991856492 hasAuthorship W2991856492A5045513298 @default.
• W2991856492 hasConcept C121608353 @default.
• W2991856492 hasConcept C126322002 @default.
• W2991856492 hasConcept C141071460 @default.
• W2991856492 hasConcept C2776305933 @default.
• W2991856492 hasConcept C2776694085 @default.
• W2991856492 hasConcept C2776755627 @default.
• W2991856492 hasConcept C2778336483 @default.
• W2991856492 hasConcept C2778424827 @default.
• W2991856492 hasConcept C2779338263 @default.
• W2991856492 hasConcept C2779429289 @default.
• W2991856492 hasConcept C2779709957 @default.
• W2991856492 hasConcept C2781413609 @default.
• W2991856492 hasConcept C509974204 @default.
• W2991856492 hasConcept C71924100 @default.
• W2991856492 hasConcept C90924648 @default.
• W2991856492 hasConceptScore W2991856492C121608353 @default.
• W2991856492 hasConceptScore W2991856492C126322002 @default.
• W2991856492 hasConceptScore W2991856492C141071460 @default.
• W2991856492 hasConceptScore W2991856492C2776305933 @default.
• W2991856492 hasConceptScore W2991856492C2776694085 @default.
• W2991856492 hasConceptScore W2991856492C2776755627 @default.
• W2991856492 hasConceptScore W2991856492C2778336483 @default.
• W2991856492 hasConceptScore W2991856492C2778424827 @default.
• W2991856492 hasConceptScore W2991856492C2779338263 @default.
• W2991856492 hasConceptScore W2991856492C2779429289 @default.
• W2991856492 hasConceptScore W2991856492C2779709957 @default.
• W2991856492 hasConceptScore W2991856492C2781413609 @default.
• W2991856492 hasConceptScore W2991856492C509974204 @default.
• W2991856492 hasConceptScore W2991856492C71924100 @default.
• W2991856492 hasConceptScore W2991856492C90924648 @default.
• W2991856492 hasLocation W29918564921 @default.
• W2991856492 hasOpenAccess W2991856492 @default.
• W2991856492 hasPrimaryLocation W29918564921 @default.
• W2991856492 hasRelatedWork W147983343 @default.
• W2991856492 hasRelatedWork W1964163166 @default.
• W2991856492 hasRelatedWork W1991550939 @default.
• W2991856492 hasRelatedWork W2015926882 @default.
• W2991856492 hasRelatedWork W2068650434 @default.
• W2991856492 hasRelatedWork W2084044230 @default.
• W2991856492 hasRelatedWork W2087470131 @default.
• W2991856492 hasRelatedWork W2105446438 @default.
• W2991856492 hasRelatedWork W2107514555 @default.
• W2991856492 hasRelatedWork W2116165374 @default.
• W2991856492 hasRelatedWork W2155961757 @default.
• W2991856492 hasRelatedWork W2164868977 @default.
• W2991856492 hasRelatedWork W2170592366 @default.
• W2991856492 hasRelatedWork W2276505229 @default.
• W2991856492 hasRelatedWork W2410069353 @default.
• W2991856492 hasRelatedWork W2591685160 @default.
• W2991856492 hasRelatedWork W2806976484 @default.
• W2991856492 hasRelatedWork W2964470563 @default.
• W2991856492 hasRelatedWork W2975005327 @default.
• W2991856492 hasRelatedWork W2976559952 @default.
• W2991856492 isParatext "false" @default.
• W2991856492 isRetracted "false" @default.
• W2991856492 magId "2991856492" @default.
• W2991856492 workType "article" @default.